Plantaginent
02 Sep 2016
Re: Am I the only one? No I don't think you missed anything but it seems that the potential take-over price is rather disappointing. I for one will not be making much on this one.
jgrjgr
02 Sep 2016
Re: Am I the only one? You are right! Takeover announced! - Just when I was thinking of adding, they are going chinese!
readyeddie
09 May 2016
Pharmaspecialist in answer to your question, no I have held these shares since 2011 and have added to them, in my personal view this company will return 0ver 100% on my investment I am already up 25% roll on a takeover..
pharmaspecialist
19 Jan 2016
Am I the only one? I am becoming convinced that hardly any investors are paying attention to this company. It has announced today that operating profits will double and earnings will be materially ahead of expectations. It also has a strong cash position and a strong global position in a high technology medical niche market. It is also expanding rapidly on an international basis including in China and its product has a chance of becoming the global standard. So what is the forward p/e for this company? 11.2 at the time of writing, and that is based on the earnings without the upgrade announced today. I don't think you can go far wrong there, especially as I expect the company to be acquired by a larger med tech company if its share price does not improve significantly above 200p where it is at the moment. Please let me know if I have missed something.
pharmaspecialist
18 Dec 2015
This must surely be a bargain now? This company is one of the global leaders in its medical niche and hasannounced today that its profits will be materially ahead of expectations as it expands into Asia . When you combine this with the hint provided in its most recent results that it could be a takeover candidate, I think it would be fair to say that it looks good value at the current price. I think this company must be off the radar or most AIM investors because it is a US company expaning into Asia working in a highly specialist area of medical technology. However, I would suggest it is well worth a look.
pharmaspecialist
22 Sep 2015
Solid results + takeover prospects. Yesterday's results were solid if unspectacular but I am sure the reason for the rise in share price today (up 12% at time of writing) is that news of the company's strategic review has put a spotlight on its valuation. It is a leader in an expanding sector of the global medical market and I reckon there are plenty of device companies which would be willing to pay more than the current share price if a deal can be agreed. I have a small shareholding.
